
Paratek Pharmaceuticals PRTK
Quarterly report 2023-Q2
added 08-03-2023
Paratek Pharmaceuticals DIO Ratio 2011-2026 | PRTK
Annual DIO Ratio Paratek Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 218 | 217 | 614 | 1.21 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.21 K | 217 | 566 |
Quarterly DIO Ratio Paratek Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 265 | 223 | - | 217 | 119 | 310 | - | 178 | 103 | 477 | - | 658 | 594 | 811 | - | 1.1 K | 1.86 K | 2.7 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.7 K | 103 | 687 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | ||
|
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
166 | $ 22.92 | 0.17 % | $ 1.07 B | ||
|
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - | ||
|
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M | ||
|
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | ||
|
Akebia Therapeutics
AKBA
|
147 | $ 1.43 | 1.78 % | $ 368 M | ||
|
BioDelivery Sciences International
BDSI
|
321 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B | ||
|
Aquestive Therapeutics
AQST
|
120 | $ 4.24 | -1.85 % | $ 453 M | ||
|
Arcutis Biotherapeutics
ARQT
|
185 | $ 24.47 | -0.24 % | $ 3.11 B | ||
|
Autolus Therapeutics plc
AUTL
|
70.7 | $ 1.58 | -1.25 % | $ 420 M | ||
|
BioXcel Therapeutics
BTAI
|
1.56 K | $ 1.2 | 4.35 % | $ 14.6 M | ||
|
bluebird bio
BLUE
|
125 | - | - | $ 546 M | ||
|
ChromaDex Corporation
CDXC
|
69.7 | - | -0.88 % | $ 598 M |